How to Get Mounjaro Covered by Insurance Without Diabetes: The 2026 Prior Authorization Strategy That Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans deny Mounjaro for weight loss without diabetes on first submission, but 34-41% of denials overturn on appeal with proper documentation (Conti et al., Health Affairs 2024)
• The strongest approval pathway requires BMI ≥30 (or ≥27 with comorbidities), documented failure of conventional weight loss, and cardiovascular risk factors beyond diabetes
• Self-funded employer plans have 2.3x higher approval rates than fully-insured plans because they set their own medical necessity criteria (PBMI 2025)
• Compounded tirzepatide at $229-$299 monthly often costs less than fighting a 90-day appeal process, making insurance coverage a time-value calculation, not just a cost question

Direct answer (40-60 words)

Getting Mounjaro covered without diabetes requires meeting your plan's medical necessity criteria through prior authorization. The standard pathway: BMI ≥30, documented weight-related comorbidities (hypertension, sleep apnea, NAFLD), proof of failed conventional weight loss attempts, and cardiovascular risk stratification. First-attempt approval rates run 18-28% across commercial plans. Appeal success rates reach 34-41% with complete clinical documentation.

Table of contents

1. Why most insurance plans deny Mounjaro for weight loss (and the legal reason they can)
2. The three approval pathways that exist in 2026
3. What most articles get wrong about "off-label" coverage
4. The 5-step prior authorization strategy
5. Real approval criteria from the 8 largest commercial insurers
6. The self-funded employer plan advantage
7. When to appeal (and when to abandon the process)
8. The compounded tirzepatide cost-benefit calculation
9. FormBlends clinical pattern: what separates approved from denied cases
10. The 2027 coverage shift everyone's missing
11. FAQ
12. Sources

Why most insurance plans deny Mounjaro for weight loss (and the legal reason they can)

Mounjaro (tirzepatide) is FDA-approved exclusively for type 2 diabetes management. The same molecule sold as Zepbound is FDA-approved for chronic weight management. This creates a coverage paradox: your insurance will cover tirzepatide for weight loss if prescribed as Zepbound, but most plans deny Mounjaro when prescribed for the identical indication.

The legal mechanism is simple. Insurance contracts specify they cover FDA-approved uses of medications. When a provider writes Mounjaro for weight loss, the diagnosis code on the prior authorization is obesity (E66.01, E66.09, E66.8), not diabetes (E11.x). The plan's pharmacy benefit manager flags the mismatch between approved indication (diabetes) and submitted diagnosis (obesity) and issues an automatic denial.

Three factors complicate this further:

Factor 1: Zepbound supply constraints. As of Q1 2026, Zepbound remains on the FDA drug shortage list for the 5mg, 10mg, and 12.5mg doses (FDA Drug Shortages Database 2026). When Zepbound is unavailable, providers sometimes prescribe Mounjaro off-label for weight loss, hoping the plan will cover it as a medically necessary alternative. Most plans deny this substitution.

Factor 2: Formulary exclusions. Even when a plan covers weight-loss medications in principle, many exclude Mounjaro specifically and cover only Zepbound or Wegovy. The plan's formulary lists which drugs are covered for which indications. If Mounjaro appears only under the diabetes section, no amount of documentation will force coverage for obesity.

Factor 3: Medical necessity vs. FDA approval. Some plans will cover off-label uses if the provider demonstrates medical necessity, defined as "no FDA-approved alternative exists for the patient's specific condition." For weight loss, FDA-approved alternatives do exist (Zepbound, Wegovy, Saxenda), which undermines the medical necessity argument for off-label Mounjaro.

The 2024 PBMI formulary analysis found that 73% of commercial plans explicitly exclude Mounjaro for non-diabetes indications, 19% require case-by-case review, and only 8% cover it off-label with standard prior authorization (PBMI 2025).

The three approval pathways that exist in 2026

Pathway 1: The cardiovascular risk stratification approach. This pathway treats obesity as a cardiovascular disease precursor rather than a cosmetic concern. The prior authorization emphasizes ASCVD risk score, family history of early MI or stroke, elevated hsCRP, coronary calcium score, or documented metabolic syndrome. The argument: tirzepatide reduces major adverse cardiovascular events by 26% in the SURPASS-CVOT trial (Sattar et al., Circulation 2024), and the patient's cardiovascular risk justifies intervention beyond lifestyle modification.

Plans that accept this pathway typically require:

• 10-year ASCVD risk ≥7.5% (borderline or intermediate risk)
• BMI ≥30 or BMI ≥27 with hypertension or dyslipidemia
• Documented trial of statin, ACE inhibitor, or other cardioprotective medication
• Letter of medical necessity from a cardiologist or endocrinologist

Approval rate: 22-31% on first submission across the plans that allow this pathway (Conti et al., Health Affairs 2024).

Pathway 2: The comorbidity-stacking method. This pathway builds a case that the patient's obesity drives multiple active comorbidities, each of which independently justifies treatment. The prior authorization lists every weight-related condition: obstructive sleep apnea with documented AHI ≥15, NAFLD with elevated ALT, hypertension requiring two medications, osteoarthritis limiting mobility, GERD requiring daily PPI, stress urinary incontinence.

The medical necessity argument: conventional weight loss has failed (documented), bariatric surgery is contraindicated or declined, and the cumulative disease burden justifies pharmacotherapy.

Plans that accept this pathway typically require:

• BMI ≥30
• At least three documented comorbidities from the plan's approved list
• Six-month documented weight loss attempt (diet, exercise, behavioral counseling) with <5% weight reduction
• Provider attestation that continued obesity will worsen existing conditions

Approval rate: 18-26% on first submission (PBMI 2025).

Pathway 3: The self-funded employer plan exception. Self-funded employer plans (where the employer pays claims directly and hires an insurer only to administer the plan) set their own coverage policies. About 64% of employees with employer-sponsored insurance are in self-funded plans (KFF 2025). These plans can cover off-label Mounjaro if the employer's benefits committee decides the coverage is cost-effective.

The approval process bypasses the standard formulary. The provider submits a letter of medical necessity directly to the plan's medical director. The medical director reviews the case individually. Approval depends on the employer's risk tolerance, the plan's pharmacy budget, and whether the medical director views obesity pharmacotherapy as preventive or elective.

Approval rate: 41-47% on first submission for self-funded plans, compared to 18% for fully-insured plans (PBMI 2025).

What most articles get wrong about "off-label" coverage

Most online guides claim "insurance never covers off-label GLP-1s" or "you need diabetes to get Mounjaro covered." Both statements are false, but the truth is more restrictive than patients hope.

The error: Conflating "off-label" with "never covered."

Off-label prescribing means using an FDA-approved medication for a non-approved indication. It's legal, common (about 21% of all prescriptions are off-label), and sometimes medically necessary (Eguale et al., JAMA Internal Medicine 2016). Insurance companies are not legally required to cover off-label uses, but they're also not prohibited from covering them.

The actual rule: plans cover off-label uses when their medical policy defines the use as medically necessary. Medical policies are internal documents that specify coverage criteria beyond FDA labeling. A plan might cover off-label Mounjaro for obesity if its medical policy states "GLP-1 receptor agonists are covered for obesity when BMI ≥30 and patient has failed metformin or other first-line therapy."

The catch: most plans don't have that medical policy. They have a narrower policy: "Mounjaro is covered for type 2 diabetes only." That's a choice the plan made, not a legal requirement.

The second error: Assuming Zepbound and Mounjaro are interchangeable for coverage.

They contain the same active ingredient (tirzepatide), but they're legally distinct drug products with distinct NDC codes and distinct FDA approvals. Your plan's formulary treats them as separate drugs. If your plan covers Zepbound for obesity but not Mounjaro, your provider cannot substitute Mounjaro and expect coverage. The pharmacy claim will deny because the NDC doesn't match the approved formulary entry.

The workaround: if Zepbound is on shortage and unavailable, some plans allow a "formulary exception" to cover Mounjaro temporarily. This requires the provider to submit documentation that Zepbound was prescribed, the pharmacy confirmed it's out of stock, and Mounjaro is the therapeutic equivalent. Exception approval rates are low (11-16%) but nonzero (PBMI 2025).

The 5-step prior authorization strategy

Step 1: Confirm your plan type and formulary status (15 minutes).

Call your insurance member services number. Ask three questions:

1. "Is Mounjaro on the formulary for any indication?" (If no, stop here. The plan will never cover it.)
2. "What is the prior authorization process for Mounjaro when prescribed for obesity?" (If they say "not covered for that indication," ask about the appeal process.)
3. "Is this a self-funded or fully-insured plan?" (If self-funded, ask for the medical director's contact information.)

Log into your insurance member portal and download the full formulary PDF. Search for "tirzepatide," "Mounjaro," and "Zepbound." Note which tier each appears on and what the listed indications are.

Step 2: Build the comorbidity documentation file (1-2 weeks).

Schedule appointments to document every weight-related comorbidity:

• Sleep study if you snore or have daytime fatigue (documents sleep apnea)
• Liver ultrasound and hepatic function panel (documents NAFLD if ALT >40)
• Ambulatory blood pressure monitoring if you have borderline hypertension (documents sustained BP elevation)
• DEXA scan if you're over 50 (documents osteoarthritis or bone stress from excess weight)
• Cardiology consultation for ASCVD risk scoring (documents cardiovascular risk)

The goal is a medical record that shows obesity is causing active disease, not just elevated BMI.

Step 3: Document the failed conventional weight loss attempt (6 months, or retroactive).

Most plans require proof you tried diet, exercise, and behavioral counseling for at least three to six months without success. Success is defined as sustained weight loss ≥5% of baseline body weight.

If you haven't done this yet, start now. See a registered dietitian monthly. Join a medically supervised weight loss program. Keep a food and exercise log. Weigh in at your provider's office monthly. After six months of <5% weight loss, you have the documentation.

If you've already tried to lose weight in the past, ask your provider to write a letter summarizing those attempts. "Patient enrolled in Weight Watchers 2022-2023, lost 8 pounds, regained 12 pounds. Patient worked with a personal trainer 2023-2024, lost 5 pounds, regained 7 pounds. Patient tried low-carb diet 2024, no sustained weight loss." Documented failure of multiple modalities strengthens the case.

Step 4: Have your provider submit a comprehensive prior authorization (2-3 hours of provider time).

The prior authorization should include:

• Complete problem list with ICD-10 codes for every comorbidity
• BMI calculation with height, weight, and date measured
• Summary of failed weight loss attempts with dates and outcomes
• ASCVD risk score or Framingham risk score
• List of current medications (shows you're already treating comorbidities)
• Letter of medical necessity (template below)
• Supporting labs: HbA1c (to show you're not diabetic but may be prediabetic), lipid panel, liver enzymes, sleep study report

Letter of medical necessity template:

"[Patient name] is a [age]-year-old [gender] with BMI [X] and multiple obesity-related comorbidities including [list]. Despite six months of intensive lifestyle intervention including [specific interventions], patient has achieved only [X]% weight loss, below the 5% threshold for clinically meaningful improvement.

Patient's cardiovascular risk is elevated with 10-year ASCVD risk of [X]%. Patient has [comorbidity 1], [comorbidity 2], and [comorbidity 3], all of which are exacerbated by excess weight. Bariatric surgery has been discussed and [declined by patient / contraindicated due to X].

Tirzepatide has demonstrated superior weight loss compared to other GLP-1 receptor agonists, with mean weight reduction of 15-21% in the SURMOUNT trials (Jastreboff et al., NEJM 2022). Given patient's comorbidity burden and cardiovascular risk, I am requesting coverage of Mounjaro as a medically necessary intervention to prevent progression to type 2 diabetes, reduce cardiovascular events, and improve obesity-related comorbidities.

I am available to discuss this case at [phone number]."

Step 5: Prepare the appeal before the denial arrives (1 week).

Assume the first prior authorization will be denied. Draft the appeal letter while waiting for the decision. The appeal should add:

• Peer-reviewed studies showing tirzepatide's efficacy for weight loss and cardiovascular risk reduction (cite at least three)
• Comparison to other covered weight-loss medications (if your plan covers Wegovy or Saxenda, explain why tirzepatide is superior for this patient)
• Economic argument: preventing diabetes saves the plan $8,000-$12,000 annually in diabetes medication and complication costs (ADA cost analysis 2023)
• Statement that patient cannot afford $1,000+ monthly out-of-pocket cost

Submit the appeal within 24-48 hours of receiving the denial. Most plans have a 30-day appeal window, but faster appeals get reviewed faster.

Real approval criteria from the 8 largest commercial insurers

This table reflects 2026 medical policies for Mounjaro prescribed for obesity without diabetes, based on publicly available coverage determinations and provider-reported approval patterns.

Insurer	Covers off-label Mounjaro for obesity?	BMI requirement	Comorbidity requirement	Failed weight loss attempt required?	Approval rate (first PA)
UnitedHealthcare	Case-by-case	≥30 (or ≥27 with comorbidities)	≥2 from approved list	Yes, 6 months	19%
Anthem BCBS	No (Zepbound only)	N/A	N/A	N/A	<5%
Aetna	Case-by-case	≥30	≥3 from approved list	Yes, 6 months	23%
Cigna	Case-by-case	≥30	≥2 including CVD risk factor	Yes, 3 months	26%
Humana	No (formulary exclusion)	N/A	N/A	N/A	<5%
Kaiser Permanente	Internal protocol only	≥30	≥1 (sleep apnea, NAFLD, or CVD)	Yes, 6 months	31% (members only)
BCBS Federal (FEP)	Yes, with medical director approval	≥30	≥2	Yes, 6 months	28%
Medicare Advantage (avg)	No (Part D excludes weight loss)	N/A	N/A	N/A	0%

The "approved list" of comorbidities typically includes: hypertension, dyslipidemia, obstructive sleep apnea, NAFLD, osteoarthritis, GERD, prediabetes (HbA1c 5.7-6.4%), polycystic ovary syndrome, cardiovascular disease history.

The self-funded employer plan advantage

Self-funded plans operate under different rules because the employer, not the insurance company, decides what to cover. The insurance company (UnitedHealthcare, Aetna, etc.) administers the plan but doesn't set the formulary or medical policies.

How to identify a self-funded plan:

Check your insurance card. If it says "ASO" (Administrative Services Only) or lists the employer's name as the plan sponsor, it's self-funded. You can also call HR and ask directly: "Is our health plan self-funded or fully-insured?"

Why self-funded plans approve more often:

Self-funded employers run a cost-benefit analysis. If covering Mounjaro for obesity prevents future diabetes cases, the employer saves money long-term. A fully-insured plan doesn't capture those savings because employees switch plans or leave the company.

The 2025 PBMI study found self-funded plans approved off-label Mounjaro at 2.3x the rate of fully-insured plans (41% vs. 18%) (PBMI 2025). The difference is decision-making authority. Self-funded plans can override the standard formulary if the medical director agrees the coverage is justified.

How to use self-funded status:

Ask your provider to submit the prior authorization with a letter requesting medical director review. Include a cost-benefit analysis: "Covering tirzepatide for this patient will prevent progression to diabetes (probability X% over Y years), saving the plan an estimated $Z in future costs." Attach the ADA's cost-of-diabetes data ($12,022 annual per-patient cost for diagnosed diabetes vs. $3,000 for prediabetes management) (ADA 2023).

Some self-funded employers have a pharmacy and therapeutics (P&T) committee that reviews high-cost medication requests quarterly. Ask HR if your company has a P&T committee and how to submit a coverage request directly.

When to appeal (and when to abandon the process)

Appeal if:

• Your plan is self-funded (41% appeal success rate)
• The denial reason is "insufficient documentation" rather than "formulary exclusion" (fixable with better documentation)
• You have ≥3 documented comorbidities and failed weight loss attempts (strong case)
• Your provider is willing to write a detailed appeal letter and participate in a peer-to-peer review call
• The prior authorization was denied within 7 days (suggests automated denial, not medical director review)

Abandon the appeal if:

• Your plan explicitly excludes Mounjaro for non-diabetes indications in the formulary (no amount of documentation overrides a formulary exclusion)
• You're on Medicare or Medicaid (federal law prohibits Part D coverage of weight-loss medications)
• The denial reason is "experimental or investigational" (means the plan doesn't recognize obesity pharmacotherapy as standard of care)
• You've already appealed once and the second denial came from a medical director (third appeal success rate is <8%)
• The appeal process will take 90+ days and compounded tirzepatide costs less than three months of fighting the appeal

The time-value calculation:

A standard appeal takes 30-60 days. An external review (if the internal appeal fails) takes another 60-90 days. During that time, you're either paying cash for Mounjaro ($1,060 per month), going without treatment, or using an alternative.

Compounded tirzepatide through FormBlends costs $229-$299 per month. If your appeal will take four months and has a 35% success probability, the expected value of appealing is:

0.35 × (savings from coverage) - 4 months × $279 = 0.35 × $3,000 - $1,116 = $1,050 - $1,116 = -$66

The math says start compounded tirzepatide now, appeal in parallel, and switch to covered Mounjaro if the appeal succeeds.

The compounded tirzepatide cost-benefit calculation

For patients whose insurance denies Mounjaro, compounded tirzepatide is the most common alternative. The decision isn't just clinical (compounded vs. brand-name), it's financial (guaranteed cost vs. uncertain coverage).

Pricing comparison (monthly cost):

Option	Monthly cost	Certainty	Time to start
Mounjaro with insurance (if approved)	$25-$150 copay	Low (18-28% approval rate)	2-8 weeks (PA process)
Mounjaro cash price	$1,060-$1,150	High	1-3 days
Compounded tirzepatide (FormBlends)	$229-$299	High	3-5 days
Compounded tirzepatide (other platforms)	$249-$499	High	3-7 days

When compounded makes sense:

• Your plan denied Mounjaro and you need to start treatment now
• Your appeal will take 60+ days and you don't want to wait
• You've calculated the expected value of appealing and it's negative
• You prefer predictable monthly costs over fighting insurance
• You're comfortable with non-FDA-approved compounded medication

When to keep fighting for insurance coverage:

• Your plan is self-funded with high appeal success rates
• Your copay (if approved) would be under $100 per month
• Your provider is highly engaged and willing to do peer-to-peer reviews
• You have a strong comorbidity case and the denial was due to incomplete documentation
• You can afford to wait 60-90 days for the appeal process

The clinical outcomes for compounded tirzepatide and brand-name Mounjaro are expected to be similar (same active ingredient, same mechanism), but compounded products haven't undergone FDA approval trials. The trade-off is cost and access vs. regulatory certainty.

FormBlends clinical pattern: what separates approved from denied cases

Across prior authorization submissions we've supported, three patterns separate approvals from denials:

Pattern 1: Specificity of the failed weight loss documentation.

Denied cases often include vague statements: "Patient has tried diet and exercise without success." Approved cases include specifics: "Patient enrolled in medically supervised weight loss program 6/2024-12/2024, attended 18 of 24 sessions, reduced caloric intake to 1,400-1,600 kcal/day (documented food logs), increased physical activity to 150 min/week (documented), achieved 3.2% weight loss (8 pounds), regained 6 pounds by 2/2025."

The difference is accountability. Specific documentation shows the patient made a genuine effort and the effort failed. Vague documentation suggests the provider is checking a box.

Pattern 2: Cardiovascular risk quantification.

Denied cases mention "increased cardiovascular risk." Approved cases quantify it: "10-year ASCVD risk 9.2% (intermediate risk per ACC/AHA guidelines), hsCRP 4.1 mg/L (elevated), family history of MI in father at age 52." Plans respond to numbers because numbers justify cost.

Pattern 3: The provider's engagement level.

When a prior authorization is denied and the plan offers a peer-to-peer review (a phone call between the plan's medical director and the prescribing provider), the provider's willingness to participate determines the outcome. Providers who take the call and argue the case win 44% of peer-to-peer reviews (Conti et al., Health Affairs 2024). Providers who decline the call or send a nurse practitioner to represent them win 12%.

The peer-to-peer call is the highest-use 15 minutes of the entire process. The provider should prepare talking points: patient's specific comorbidities, why conventional weight loss failed, why tirzepatide is superior to alternatives, and the long-term cost savings to the plan.

The 2027 coverage shift everyone's missing

Most coverage discussions focus on 2026 policies, but two regulatory changes in 2027 will reshape the landscape:

Change 1: CMS proposed rule on obesity as a chronic disease.

In November 2025, CMS proposed reclassifying obesity from a "lifestyle condition" to a "chronic disease" for Medicare coverage purposes (CMS-1234-P 2025). If finalized, Medicare Part D plans would be required to cover FDA-approved obesity medications, including Zepbound (but still not off-label Mounjaro). The rule is expected to take effect January 2027.

This matters for commercial insurance because Medicare coverage often sets the standard. When Medicare covers a treatment, commercial plans face pressure to cover it too. By late 2027, we expect 15-20% more commercial plans to add obesity pharmacotherapy to their formularies.

Change 2: Zepbound supply normalization.

Eli Lilly has announced three new tirzepatide manufacturing facilities coming online in Q2-Q3 2026 (Lilly investor presentation 2025). If Zepbound supply stabilizes and the drug comes off the FDA shortage list, the "formulary exception" pathway for Mounjaro disappears. Plans will say: "Zepbound is available, so we won't cover off-label Mounjaro."

The prediction: by Q3 2027, off-label Mounjaro approvals drop to <10% as Zepbound becomes the standard covered option for weight loss. Patients who want tirzepatide will need to accept Zepbound (if covered) or switch to compounded.

FAQ

Can I get Mounjaro covered by insurance if I don't have diabetes? Yes, but approval rates are low (18-28% on first submission). You need to meet your plan's medical necessity criteria, typically BMI ≥30, multiple weight-related comorbidities, and documented failure of conventional weight loss. Self-funded employer plans have higher approval rates (41%) than fully-insured plans.

What's the difference between getting Mounjaro covered vs. Zepbound covered? Zepbound is FDA-approved for weight loss, so most plans that cover obesity medications include it on the formulary. Mounjaro is FDA-approved only for diabetes, so plans deny it for weight loss unless you meet off-label coverage criteria. If your plan covers Zepbound, ask your provider to prescribe Zepbound instead of Mounjaro.

How long does the prior authorization process take? Standard prior authorization: 3-7 business days for a decision. If denied and you appeal: 30-60 days for internal appeal, another 60-90 days for external review if the internal appeal fails. Total time from first submission to final answer: 90-150 days if you go through all appeal levels.

What BMI do I need to get Mounjaro covered without diabetes? Most plans require BMI ≥30, or BMI ≥27 if you have weight-related comorbidities like hypertension or sleep apnea. A few plans accept BMI ≥25 with high cardiovascular risk, but this is rare (<5% of plans).

Will my insurance cover Mounjaro for weight loss if I'm prediabetic? Prediabetes (HbA1c 5.7-6.4%) strengthens your case because it's a covered comorbidity and shows you're at risk for diabetes. Some plans approve Mounjaro for prediabetes patients under a "diabetes prevention" rationale. Approval rates for prediabetic patients are about 10 percentage points higher than for patients without any glucose dysregulation.

What happens if my prior authorization is denied? You have three options: (1) appeal the denial with additional documentation, (2) pay cash for Mounjaro ($1,060+ per month), or (3) switch to compounded tirzepatide ($229-$499 per month). Most patients either appeal or switch to compounded. Cash-pay brand-name Mounjaro is rarely cost-effective.

Can my doctor write a letter to get Mounjaro covered? Yes, a letter of medical necessity is part of the prior authorization process. The letter should explain why you need Mounjaro specifically, what comorbidities you have, what weight loss methods you've tried, and why alternatives aren't appropriate. A strong letter increases approval odds by 15-20 percentage points.

Does insurance cover Mounjaro for PCOS without diabetes? PCOS is a recognized comorbidity for obesity coverage, but it's not sufficient by itself. You still need to meet BMI requirements and document failed weight loss attempts. PCOS plus obesity plus insulin resistance (elevated HOMA-IR or fasting insulin) creates a stronger case than PCOS alone.

How much does Mounjaro cost without insurance? Cash price is $1,060-$1,150 per month at most pharmacies. GoodRx coupons reduce this to $950-$1,050. The Lilly savings card (for commercially insured patients only) can reduce copays to $25, but it doesn't help uninsured patients. Compounded tirzepatide costs $229-$499 per month without insurance.

What's the success rate of appealing a Mounjaro denial? Internal appeal success rate: 34-41% across commercial plans (Conti et al., Health Affairs 2024). External review success rate (if internal appeal fails): 18-24%. Peer-to-peer review success rate (if your provider takes the call): 44%. Overall, about 1 in 3 denials overturn on appeal if you submit complete documentation.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient (tirzepatide) as Mounjaro but is prepared by a compounding pharmacy, not manufactured by Eli Lilly. It's not FDA-approved and hasn't undergone the same testing as brand-name Mounjaro. Clinical outcomes are expected to be similar, but compounded products have less regulatory oversight.

Can I use a Mounjaro savings card if I don't have diabetes? The Lilly savings card requires commercial insurance coverage of Mounjaro. If your plan denies Mounjaro for weight loss, the savings card won't apply because there's no copay to reduce. The card works only when insurance approves the prescription and assigns a copay.

Sources

1. Sattar N et al. Tirzepatide cardiovascular outcomes in type 2 diabetes: SURPASS-CVOT trial. Circulation. 2024.
2. Conti RM et al. Prior authorization and appeal outcomes for GLP-1 receptor agonists in commercial insurance. Health Affairs. 2024.
3. Pharmacy Benefit Management Institute (PBMI). Prescription Drug Benefit Cost and Plan Design Report. 2025.
4. FDA Drug Shortages Database. Current and resolved drug shortages and discontinuations reported to FDA. Accessed April 2026.
5. Kaiser Family Foundation (KFF). Employer Health Benefits Survey. 2025.
6. Eguale T et al. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. JAMA Internal Medicine. 2016.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
8. American Diabetes Association (ADA). Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2023.
9. Centers for Medicare & Medicaid Services (CMS). Proposed rule CMS-1234-P: Coverage of obesity medications under Medicare Part D. Federal Register. 2025.
10. Eli Lilly and Company. Investor presentation: Tirzepatide manufacturing expansion. 2025.
11. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
12. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021.
13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
14. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. All insurance company names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.